Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease
- PMID: 31415492
- PMCID: PMC6818702
- DOI: 10.15585/mmwr.mm6832a4
Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease
Abstract
Lyme disease is a tickborne zoonosis for which serologic testing is the principal means of laboratory diagnosis. In 1994, the Association of State and Territorial Public Health Laboratory Directors, CDC, the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Council of State and Territorial Epidemiologists, and the National Committee for Clinical Laboratory Standards convened the Second National Conference on Serologic Diagnosis of Lyme Disease (1).
Conflict of interest statement
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
References
-
- Association of State and Territorial Public Health Laboratory Directors. In: proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease; October 27–29, 1994; Dearborn, MI. Washington, DC: Association of State and Territorial Public Health Laboratory Directors; 1994.
-
- CDC. Notice to readers: recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995;44:590–1. - PubMed
-
- Food and Drug Administration. FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses. [News release]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2019. https://www.fda.gov/news-events/press-announcements/fda-clears-new-indic...
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical